Short Interest in International Stem Cell Corp. (OTCMKTS:ISCO) Grows By 21.9%

International Stem Cell Corp. (OTCMKTS:ISCO) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 39 shares, a growth of 21.9% from the December 31st total of 32 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 3,120 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 3,120 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are short sold.

International Stem Cell Price Performance

ISCO opened at $0.17 on Thursday. International Stem Cell has a one year low of $0.08 and a one year high of $0.27. The business has a 50 day simple moving average of $0.14 and a two-hundred day simple moving average of $0.14. The firm has a market capitalization of $1.33 million, a price-to-earnings ratio of -8.32 and a beta of 0.24.

International Stem Cell Company Profile

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.